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1. Introduction
The relative frequency of lymphoma types varies in different geographic region. Human T-
cell lymphotropic virus type I (HTLV-I) infection is endemic in south-western Japan which
leads to a high frequency of adult T-cell leukemia/lymphoma (ATLL). As compared to the
West, East Asian countries have higher relative frequencies of T- and natural killer (NK)-cell
lymphomas, which account for about 15-20% of non-Hodgkin lymphoma after excluding
ATLL in some Japanese series [1-5]. Accordingly, a higher frequency of T- and NK/T-cell
leukemia would be expected in East Asia. As compared to B-cell lymphomas, T- and NK/T-
cell neoplasms more frequently occur at extranodal locations, and may occasionally present
as leukemia, either with or without concomitant lymphoma.
There are around 20 entities and variants of T- and NK/T-cell neoplasms in the 4th edition of
World Health Organization (WHO) classification of lymphoid neoplasms [6]. Table 1 lists
the T- and NK/T-cell neoplasms which may have leukemic presentation. The first category
comprises entities that are predominantly leukemic including T-cell prolymphocytic leuke‐
mia (T-PLL), T-cell large granular lymphocytic leukemia (T-LGLL) and aggressive NK-cell
leukemia (ANKL). The second category includes neoplasms that frequently present with
concurrent lymphoma and leukemia such as T lymphoblastic leukemia/lymphoma (T-LBL),
ATLL and Sézary syndrome. The third category includes T-cell lymphoma with secondary
peripheral blood involvement such as unspecified peripheral T-cell lymphoma (PTCL-NOS)
progressing to a leukemic phase and very rarely extranodal NK/T-cell lymphoma (ENKTL)
with peripheral blood involvement, which might overlap with ANKL [7]. In the East Asian
region other than Japan, ATLL is extremely rare and the discussion on this entity is covered
in the other chapters. Sézary syndrome is extremely rare in this region as well. Accordingly
we will not discuss these two entities in this chapter.
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A. Predominantly leukemic
1. T-cell prolymphocytic leukemia (T-PLL)
2. T-cell large granular lymphocytic leukemia (T-LGLL)
3. Aggressive NK-cell leukemia (ANKL)
B. Concurrent lymphoma/leukemia
1. T lymphoblastic lymphoma/leukemia (T-LBL)
2. Adult T-cell lymphoma/leukemia (ATLL)
3. Sézary syndrome
C. Lymphoma with secondary peripheral blood involvement
1. Peripheral T-cell lymphoma with peripheral blood involvement
2. Extranodal NK/T-cell lymphoma with peripheral blood involvement
Table 1. T- and NK/T-cell neoplasms with leukemic presentation.
There are very few reports systemically reviewing the whole spectrum of T- and NK/T-cell
neoplasms with leukemic presentation in the East Asia. In a prospective study of chronic
lymphoproliferative disorders in Hong Kong in an 18-month period from January 1995 to
June 1996, there were a total of 34 cases of chronic lymphoproliferative disorder, estimated
at 0.54 case per million populations per year, as compared to 245 new cases of acute myeloid
leukemia in the same study period [8]. Of these 34 cases, the majority were B-cell neoplasms
with the remaining 3 (9%) cases being T-cell leukemias including one case each of T-PLL,
Sézary syndrome and T-LGLL [8]. In our recent retrospective study of 718 consecutive pa‐
tients with lymphoid neoplasms in a single institution in Taiwan, the frequency of T- and
NK/T-cell neoplasms with leukemic presentation was 13.1% (18 of 137 patients) [9]. Our
study showed that cases with concurrent lymphoma, higher absolute leukemic cell counts,
and elevated lactate dehydrogenase level carried a poorer prognosis. The survival of pa‐
tients with leukemic presentation was dichotomous, with a very poor prognosis for patients
with T-LBL, T-PLL, ANKL, ATLL in acute phase, and PTCL-NOS; while those with T-LGLL
and ATLL in chronic phase had a favorable outcome.
Table 2 summarizes the relative frequency of various T- and NK/T-cell leukemia in different
countries in the East Asia [1,4,9]. As mentioned previously, T- and NK/T-cell neoplasms ac‐
count for 15-20% of lymphomas in this region. The relative frequency of T-LBL among T-cell
neoplasms is low in Taiwan and Japan at less than 10%, but it is high at 23.77% (208 of 875
cases) in Korea, which is partly due to the inclusion of all lymphoid neoplasms including T-
cell acute lymphoblastic leukemia in that Korean study [4]. T-PLL is very rare in all 3 coun‐
tries with a relative frequency of less than 1% among T-cell neoplasms. T-LGLL and ANKL
are also rare with a frequency of less than 1% except for a higher frequency of the former in
Taiwan and the latter in Korea, respectively. The higher relative frequency of T-LGLL in our
series in Taiwan is probably due to a higher interest of this entity in our laboratory with con‐
firmation of suspicious cases by T-cell receptor (TCR) gene rearrangement and/or flow cy‐
tometry immunophenotyping (aberrancy in T-cell antigen expression or clonal by flow
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cytometric TCR-Vβ repertoire analysis) [10]. While in other pathology laboratories, such cas‐
es might either be unrecognized or diagnosed solely by hematologists without marrow tre‐
phine biopsy and thus not being enrolled in the pathology files for lymphoma analysis. In
the following sections, we will discuss each specific T- and NK/T-cell neoplasm.











T-LBL 2.92% (n=4) 6.91% (n=55) 9.86% (n=55) 6.62% (n=19) 23.77% (n=208)
T-PLL 0.73% (n=1) 0.25% (n=2) 0.36% (n=2) 0.35% (n=1) 0.57% (n=5)
T-LGL leukemia 5.10% (n=7) 0.25% (n=2) 0.36% (n=2) - 0.23% (n=2)
ANKL 0.73% (n=1) 0.38% (n=3) 0.54% (n=3) 0.70% (n=2) 3.31% (n=29)
ATLL 2.92% (n=4) 29.90% (n=238) Excluded 14.29% (n=41) 0.11% (n=1)
*Data of various T- and NK-cell neoplasms are presented as percentage (case number) among the total number of T-
and NK-cell neoplasms in each country.
Columns Japan-1A and -1B are from the same reference with exclusion of ATLL cases in the column of Japan-1B.
Table 2. Relative frequency of various T- and NK/T-cell leukemia among T-cell neoplasms in representative East Asian
countries.
2. T Lymphoblastic Leukemia/Lymphoma (T-LBL)
T-LBL is a rare neoplasm occurring more commonly in adolescents, accounting for 1-4%
among malignant lymphomas in East Asia [1,2,4,5,9]. Patients with T-LBL usually present
with a very high leukemic cell count (frequently over 150,000/μL), and often with a large
mediastinal mass [9]. The diagnosis is often straightforward with typical clinical features
and numerous blasts in the peripheral blood with a fine chromatin pattern and irregular nu‐
clear contours (Fig. 1A). Phenotypically, the neoplastic cells express cytoplasmic but not sur‐
face CD3; and they frequently co-express CD4 and CD8. The most important and reliable
immature cell marker is terminal deoxynucleotidyl transferase (TdT), which could be used
either in immunohistochemistry or flow cytometry [11]. The other immature markers are
CD1a, CD34 and CD99 [12,13]. Immunohistochemically, occasional cases of T-LBL may not
express TdT, but instead, express CD34 and/or CD99 [14]. The immunophenotype of T-LBL
and T-cell acute lymphoblastic leukemia are identical but differ in frequency, with a higher
rate of later phases of development (cortical or mature immunophenotype) in T-LBL, which
is probably reflecting the higher rate (> 90%) of mediastinal tumors [15].
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Figure 1. Photomicrographs of representative cases in the peripheral blood smear of A) T-LBL with indented nuclei, B)
T-PLL of small cell variant without nucleoli, C) T-LGLL with usual LGL morphology containing azurophilic cytoplasmic
granules, D) T-LGLL with atypical morphology characterized by irregular nuclear contours resembling a flower, E) reac‐
tive NK lymphocytosis and F), ANKL.
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3. T-cell Prolymphocytic Leukemia (T-PLL)
T-PLL is  rare,  representing  around 2%  of  mature  lymphocytic  leukemia  in  adults  over
the age of  30  in  the  West  with a  median age of  65  [16].  The main disease features  are
splenomegaly, lymphadenopathy, hepatomegaly, skin lesions, and a high leukocyte count
comprising small to medium-sized nucleolated prolymphocytes with cytoplasmic protru‐
sions or blebs but devoid of granules (Fig. 1B). Small cell variant with small, less typical
cells  and an indistinct  nucleolus has been recognized in 20% cases [16].  T-PLLs account
for less than 1% of T-  and NK-cell  lymphomas in East  Asia.  The clinical  manifestations
and  immunophenotype  of  T-PLL  in  Japan  are  similar  to  those  of  the  Western  cases
[17-19]. However, there is a significantly higher frequency of tumor cells in Japanese cas‐
es expressing HLA-DR than that of  Western cases [17].  Chromosome 14q11 abnormality
and trisomy 8q,  which are  frequently  seen in  T-PLL of  Western countries  (70-80%),  are
not  common in  Japan [18].  Furthermore,  a  substantial  number  of  T-PLL cases  in  Japan
shows  abnormal  expression  of  TCL1A,  probably  due  to  rearrangement  of  TCL1  gene,
which may serve as a useful marker for diagnosing T-PLL [19]. In contrast to the aggres‐
sive clinical courses observed in Western T-PLL patients, Kameoka et al.  reported that 6
out  of  13  Japanese  patients  experienced  an  indolent  course.  Interestingly,  the  clinical
course  closely  correlated  with  morphology;  86%  cases  of  typical  morphology  were  ag‐
gressive, whereas 83% of small-cell variant were indolent [17]. Studies on more cases are
needed  to  see  if  Japanese  T-PLL constitutes  a  variant  of  T-PLL.  In  East  Asia  countries
other than Japan, there are only scanty reports on T-PLL, either included in a small case
series or as a single case report [9, 20].
4. T-cell Large Granular Lymphocytic Leukemia (T-LGLL)
Large granular lymphocytes (LGLs) are medium to large-sized lymphocytes with azuro‐
philic cytoplasmic granules that normally comprise 10-15% of the peripheral blood mon‐
onuclear cells (PBMCs) and serve as the main effector cells of cell-mediated cytotoxicity.
The majority (85%) of these LGLs are NK-cells with the remaining minority being CD8-
positive  cytotoxic  T-cells  [21].  LGL  lymphoproliferation  may  be  reactive  or  neoplastic;
and reactive LGL lymphoproliferation occurs most commonly in patients with viral infec‐
tion  such  as  cytomegalovirus  infection  and  infectious  mononucleosis,  autoimmune  dis‐
ease  or  an  underlying  malignancy  [10,22].  In  the  2008  WHO  classification  scheme,  T-
LGLL is defined as a heterogeneous disorder characterized by a persistent (> 6 months)
increase  in  the  number  of  LGL  in  the  peripheral  blood,  usually  between  2-20  x109/L,
without  a  clearly  identified  cause  [23].  In  cases  with  absolute  LGL  count  less  than  2
x109/L, the diagnosis of T-LGLL could be established if clonal T-cell lymphoproliferation
is  confirmed,  either  by  TCR gene rearrangement  and/or  flow cytometry  immunopheno‐
typing (aberrancy in T-cell antigen expression or clonal by flow cytometric TCR-Vβ rep‐
ertoire analysis) [10,24-28]. In most instances, the morphology of the leukemic cells in T-
LGLL is indistinguishable from that of the normal LGLs (Fig. 1C), with the exception of
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extremely  rare  examples  showing  markedly  pleomorphic  nuclei  indicating  a  neoplastic
lymphoproliferation (Fig. 1D) [29].
A recent study led by Prof. Kwong YL from Hong Kong characterized 22 Chinese T-LGLL
patients in his institution in Hong Kong and found that the most important indication for
treatment of their patients was anemia, in contrast to neutropenia in Western patients [30].
Compiling their cases with 88 Asian patients in comparison with 272 Western patients iden‐
tified from the literature, they found that Asian patients had more frequent anemia (66/110,
60% vs. 113/240, 47%; p=0.044), attributable to a much higher incidence of pure red cell apla‐
sia (PRCA; 52/110, 47% vs. 6/143, 4%; p<0.001) [30]. On the other hand, Western patients pre‐
sented more frequently with neutropenia (146/235, 62% vs. 33/110, 30%; p<0.001) and
splenomegaly (99/246, 40% vs. 16/110, 15%; p<0.001) [30]. Notably, Western patients were
about eight to ten times more likely than Asian patients to have rheumatoid arthritis (73/272,
27% vs. 4/106, 4%; p<0.001) and recurrent infections (81/272, 30% vs. 3/107, 3%; p<0.001) [30].
They concluded that different disease mechanisms might be involved in T-LGLL in different
populations.
Table 3 summarizes the laboratory and clinical findings of T-LGLL in Taiwan, Hong Kong
and the West. Our very recent study of 17 Taiwanese patients with T-LGLL showed a higher
mean hemoglobin level (10.5 vs. 8.1 g/dL) and a lower rate of anemia (8/17, 47% vs. 17/22,
77%; p=0.028) as compared to the Chinese patients in Hong Kong; while the frequency of
anemia in our patients was similar to that (113/227, 49.8%) of the Western patients (p= 0.988)
[10]. Because anemia was not a major problem in our patients and thus bone marrow aspira‐
tion/biopsy was performed only in 8 patients. Even so, our cohort of patients showed a low‐
er rate of PRCA as compared to the Hong Kong series (2/8, 25% vs. 17/22, 68%; p=0.035).
Interestingly, in our small series of patients, the frequency of PRCA was higher than that
(6/143, 4.2%) of the Western patients (p= 0.010). There were no other statistically significant
laboratory and clinical parameters between Taiwanese vs. Hong Kong Chinese or Taiwa‐
nese vs. Western T-LGLL patients. More studies from East Asian patients are warranted to
see if there is a genuine ethnic difference in patients with T-LGLL, particularly in terms of
the frequency of anemia and PRCA.
Apart from arising as de novo neoplasms, T-LGLL may arise after hematopoietic stem cell
or solid organ transplantation [31-38]. Notably, most of the reported cases of T-LGLL af‐
ter hematopoietic stem cell transplantation are from East Asia. Prof. Kwong’s group from
Hong Kong recently reported the largest series of 7 such patients who did not have cyto‐
penia, autoimmune phenomenon or organ infiltration, features typical of de novo T-LGLL
[39].  Excluding  1  patient  died  from  cerebral  relapse  of  the  original  lymphoma,  the  re‐
maining 6 patients had remained asymptomatic with stable LGL counts for long periods
not  requiring  any  specific  treatment.  T-LGLL  occurring  after  hematopoietic  stem  cell
transplantation  seems  to  be  distinct  from  de  novo  T-LGLL  and  may  have  a  different
pathogenesis and clinical course.
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Male 12 14 125
Female 5 8 146 0.668 0.050
Age (mean ± SE of the mean, years) 62.1 ± 4.1 52.3 ± 3.2 0.121
Hemoglobin
Mean ± SE of the mean (g/dL) 10.5 ± 0.7 8.1 ± 0.7 0.019
Low(<10 g/dL) 8 17 113 0.028 0.988
Neutrophil count
Mean ± SE of the mean (x109/L) 2.7 ± 0.5 3.4 ± 1.0 0.479
Low (<1.5x109/L) 8 8 146 0.523 0.218
LGL count
Mean ± SE of the mean (x109/L) 4.5 ± 1.2 4.8 ± 0.7 0.523
High (>2x109/L) 11 14 133 0.980 0.110
Platelet count
Mean ± SE of the mean (x109/L) 223 ± 31 204 ± 28 0.989
Low (<150x109/L) 7 5 47 0.337 0.075
Hepatomegaly
Present 3 5 35
Absent 7 17 211 0.659 0.169
Splenomegaly
Present 2 8 99
Absent 8 14 147 0.335 0.199
Pure red cell aplasia
Present 2 15 6
Absent 6 7 137 0.035 0.010
Rheumatoid arthritis
Present 1 0 73
Absent 13 22 199 0.203 0.100
Autoimmune phenomena
Present 0 1 5
Absent 14 21 267 0.418 0.608
Data from the Western series is based on the report by Prof. Kwong et al [30].
Abbreviation: HK, Hong Kong; SE, standard error.
The statistical analyses of data were performed by student t test or chi square test where appropriate (SPSS, Chicago,
IL, USA.)
Table 3. Comparison of T-LGLL in Hong Kong, China, Taiwan and West
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In patients with solid organ transplantation clonal T-LGL proliferation seems to be not un‐
common. Sabnani et al. found that 71% (10/14) cardiac and 44% (4/9) renal transplant pa‐
tients had clonal expansion of T-LGL cells but without evidence of either allograft rejection
or a viral syndrome. Constitutional symptoms were present in 30% of these patients. Ane‐
mia was seen in 75% of renal transplant and 10% of cardiac transplant patients, but none of
these patients had significant neutropenia. They believe that this monoclonality is not a true
form of post-transplant lymphoproliferative disorder. Constant antigenic stimulus such as a
cytomegalovirus reactivation may be the underlying etiology of clonal T-LGL expansion
and may contribute to cytopenias and fatigue seen in transplant patients [38].
5. Aggressive NK-cell Leukemia (ANKL)
ANKL is a systemic proliferation of NK-cells, almost always associated with Epstein-Bar vi‐
rus (EBV) and an aggressive clinical course [40]. This catastrophic disease is observed almost
exclusively in Asian patients who are usually very ill on presentation, with pyrexia, jaun‐
dice, pancytopenia, skin infiltration, lymphadenopathy and hepatosplenomegaly [40,41].
The most commonly involved sites are peripheral blood, bone marrow, liver and spleen.
The leukemic cells may show a wide range of appearance from normal-looking LGL as seen
in reactive NK lymphocytosis (Fig. 1E) to atypical (e.g. irregular nuclear foldings, very large
size) or immature (e.g. open chromatin, distinct nucleoli) morphological features (Fig. 1F)
even in an individual case [42]. The number of neoplastic cells in the peripheral blood and
bone marrow can be limited or numerous, from less than 5% to greater than 80% of lympho‐
cytes [42]. Furthermore, there are cases with overlapping features with ENKTL [43,44]. Ac‐
cordingly, ANKL has also been called aggressive NK-cell lymphoma/leukemia; however,
patients with ANKL are younger and the incidence of skin involvement is significantly low‐
er than ENKTL. It is currently unclear whether ANKL is the leukemic counterpart of
ENKTL [40].
Phenotypically, the leukemic cells of ANKL in a Japanese series of 22 cases were character‐
ized by the expression of CD2, cytoplasmic CD3, CD56 and HLA-DR with frequent expres‐
sion of CD7 (14/19 cases, 74%), CD8 and CD16. They did not express surface CD3, CD4, CD5
or CD25 [45]. Interestingly, in a Korean series of 20 cases, CD7 antigen loss was detected in
10 patients (50%) [46]. The Korean investigators claimed that, in conjunction with the cyto‐
genetic findings, this characteristic immunophenotypic finding could serve as a reliable
marker for the timely diagnosis in 75% of ANKL [46]. However, there were no statistically
significant difference in the clinical or laboratory parameters between the CD7+ and the
CD7- ANKL patients. To our knowledge, there are only 2 reports of ANKL from Taiwan,
and the leukemic cells in 6 of 7 (86%) cases expressed CD7 [47,48]. No statistically significant
difference on CD7 expression was identified between ANKL cases in Taiwan, Japan or Ko‐
rea (Fishers' exact test).
The  great  majority  of  ANKL is  associated with  EBV--  85% (11/13)  in  a  Japanese  series,
88% (14/16)  in  a  Korean series  and 71% (5/7)  compiled from the  two reports  from Tai‐
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wan [45,47-49]. The EBV infection in ANKL is an episomal form, indicating a clonal inte‐
gration  into  leukemic  cells.  Prof.  Ko  et  al.  compared  the  clinicopathological
characteristics  of  EBV-negative  ANKL  patients  with  those  of  EBV-positive  ANKL  pa‐
tients  in  Korea  and  reviewed  the  literature  for  reports  on  EBV-negative  ANKL  cases.
They found that EBV-negative and EBV-positive ANKL patients had similar clinical and
pathological  characteristics,  but  EBV-negative  patients  had  a  longer  survival  than  EBV-
positive patients (11.5 vs. 1.5 months, respectively). EBV-negative patients achieved com‐
plete  remission,  but  tumors  often  relapsed  after  a  short  interval,  indicating  a  less
aggressive clinical course than EBV-positive ANKL [49].
6. Mature T- and NK/T-cell lymphoma with peripheral blood
involvement
The most common T-cell lymphoma with peripheral blood involvement is ATLL and is dis‐
cussed in the previous chapters. The other T-cell lymphoma with peripheral blood involve‐
ment is Sézary syndrome, which is characterized by the triad of erythroderma, generalized
lymphadenopathy and the presence of clonally related T-cells with cerebriform nuclei (Séz‐
ary cells) in skin, lymph nodes and peripheral blood [50]. Very rarely, PTCL-NOS and
ENKTL may progress to bone marrow and peripheral blood involvement, usually in the ter‐
minal stage of disease [7,9].
7. Conclusion
In this chapter, we review and analyze various types of T- and NK/T-cell leukemias in the
East Asia. Several of these rare neoplasms have not been reported in some East Asian coun‐
tries yet. Interestingly, there are certain features in some entities, such as T-LGLL, that are
distinct from the Western population. More epidemiological, clinicopathological and genetic
studies on these rare neoplasms are warranted.
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